GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Danaher Corp (NYSE:DHR) » Definitions » Total Stockholders Equity

DHR (Danaher) Total Stockholders Equity : $50,849 Mil (As of Mar. 2025)


View and export this data going back to 1986. Start your Free Trial

What is Danaher Total Stockholders Equity?

Danaher's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $50,849 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Danaher's Book Value per Share for the quarter that ended in Mar. 2025 was $71.06. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Danaher's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.32.

Danaher Total Stockholders Equity Historical Data

The historical data trend for Danaher's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Danaher Total Stockholders Equity Chart

Danaher Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39,766.00 45,167.00 50,082.00 53,486.00 49,543.00

Danaher Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53,442.00 49,897.00 51,299.00 49,543.00 50,849.00

Danaher  (NYSE:DHR) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Danaher's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(50849-0)/715.600
=71.06

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Danaher's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(501 + 15976) / 50849
=0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Danaher Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Danaher's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Danaher Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Danaher Corp (NYSE:DHR) » Definitions » Total Stockholders Equity
Comparable Companies
TMO IDXX A IQV MTD NTRA WAT DGX LH ILMN XSWX:LONN SHSE:603259 XPAR:BIM ICLR RVTY XPAR:ERF QGEN MEDP EXAS ASX:SHL
Traded in Other Exchanges
DHR:Mexico 1DHR:Italy DAPd:UK 0R2B:UK DAP:Germany DAP:Germany DAP:Germany DHER34:Brazil DHRC:Austria
Address
2200 Pennsylvania Avenue, North West, Suite 800W, Washington, DC, USA, 20037-1701
Website
https://www.danaher.com
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Executives
Alan G Spoon director 1150 15TH ST NW, WASHINGTON DC 20071
Brian W Ellis officer: Senior Vice President - GC 2200 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20037
Daniel Raskas officer: VP-Corporate Development 2099 PENNSYLVANIA AVENUE, NORTHWEST, WASHINGTON DC 20006
Georgeann Couchara officer: SVP, Human Resources 2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Linda Filler director 2200 PENNSYLVANIA AVE NW, SUITE 800W, WASHINGTON DC 20037
Matthew Mcgrew officer: EVP & Chief Financial Officer 2200 PENNSYLVANIA AVENUE, NW, SUITE 800 W, WASHINGTON DC 20010
Rainer Blair officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, NW, SUITE 800W, WASHINGTON DC 20037
Joakim Weidemanis officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Walter G Lohr director DANAHER CORP, 2099 PENNSYLVANIA AVE NW 12TH FL, WASHINGTON DC 20006
Teri List director 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Jose-carlos Gutierrez-ramos officer: SVP, Chief Scientific Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Raymond C Stevens director 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Jennifer Honeycutt officer: Executive Vice President 2200 PENNSYLVANIA AVENUE, SUITE 800W, WASHINGTON DC 20037
Feroz Dewan director C/O ARENA HOLDINGS MANAGEMENT LLC, 119 FIFTH AVENUE - 8TH FLOOR, NEW YORK NY 10003
Mitchell P Rales director, officer: Chairman of Exec. Committee 11790 GLEN ROAD, POTOMAC MD 20854